Wang Jeff, Wu Daphne, Shen Wei-Chiang
Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles 90033, USA.
Pharm Res. 2002 May;19(5):609-14. doi: 10.1023/a:1015397811161.
To synthesize a series of reversible fatty acid-desmopressin (DDAVP) conjugates and to study their structure-activity relationship as anti-diuretic drugs.
Seven fatty acid conjugates of DDAVP were prepared using various reversible lipidization reagents as described in our previous reports. All products were purified by acid precipitation and/or size-exclusion chromatography. Reversed-phase HPLC was used to evaluate their purity and lipophilicity. The anti-diuretic efficacy of these fatty acid conjugates was assessed in vasopressin-deficient Brattleboro rats. Four selected conjugates, i.e., DPA, DPH, DPD and DPP (acetic, hexanoic. decanoic, and palmitic acid conjugate, respectively), along with DDAVP itself were used in Caco-2 cell uptake studies and their degradation and the regeneration of active DDAVP were investigated using an in vitro liver slice metabolic system coupled with a HPLC assay.
All fatty acid-DDAVP conjugates were more lipophilic than DDAVP as examined by HPLC analyses. When cysteine was used as the linker, the capacity index (k', a measure of lipophilicity) of the conjugates was linearly correlated with the number of carbons in the fatty acid chain. The anti-diuretic activity of the conjugates was correlated with the length of the fatty acid chain, with C10 as the minimal requirement for possessing the enhanced anti-diuretic activity. Among the seven fatty acid conjugates, palmitic acid conjugate was the most potent DDAVP derivative. Removal of carboxyl group from the cysteine linker completely abolished the enhancement of the activity. The extent of cellular uptake also positively correlated with the lipophilicity of the conjugates. The metabolism of DDAVP, DPH, DPD, and DPP by liver slices all followed first order kinetics with half-life of 0.30, 0.01, 0.06 and 3.44 hr, respectively. The degradation rates of DPH and DPD in the liver slice incubation were much faster than that of DDAVP and therefore an accumulation of regenerated DDAVP in the media was observed. In contrast, DPP was metabolized much slower than DDAVP and, consequently, no significant accumulation of regenerated DDAVP could be detected.
Conjugation of DDAVP with fatty acids increased the lipophilicity and the anti-diuretic activity of this peptide drug. The anti-diuretic activity of lipidized DDAVP was dependent on the chain length of the fatty acid, as well as the structure of the linker in the conjugate. The preservation and enhancement of the in vivo antidiuretic activity of the conjugates is most likely due to a combination of an improved pharmacokinetic behavior and a concurrent regeneration of active DDAVP in tissues.
合成一系列可逆脂肪酸 - 去氨加压素(DDAVP)缀合物,并研究其作为抗利尿药物的构效关系。
如我们之前的报告所述,使用各种可逆脂质化试剂制备了七种DDAVP的脂肪酸缀合物。所有产物通过酸沉淀和/或尺寸排阻色谱法进行纯化。采用反相高效液相色谱法评估其纯度和亲脂性。在缺乏血管加压素的布拉特洛维大鼠中评估这些脂肪酸缀合物的抗利尿功效。四种选定的缀合物,即DPA、DPH、DPD和DPP(分别为乙酸、己酸、癸酸和棕榈酸缀合物),与DDAVP本身一起用于Caco - 2细胞摄取研究,并使用体外肝切片代谢系统结合高效液相色谱分析研究它们的降解以及活性DDAVP的再生。
通过高效液相色谱分析,所有脂肪酸 - DDAVP缀合物比DDAVP更具亲脂性。当半胱氨酸用作连接子时,缀合物的容量指数(k',亲脂性的一种度量)与脂肪酸链中的碳原子数呈线性相关。缀合物的抗利尿活性与脂肪酸链的长度相关,C10是具有增强抗利尿活性的最低要求。在七种脂肪酸缀合物中,棕榈酸缀合物是最有效的DDAVP衍生物。从半胱氨酸连接子上去除羧基完全消除了活性的增强。细胞摄取程度也与缀合物的亲脂性呈正相关。肝切片对DDAVP、DPH、DPD和DPP的代谢均遵循一级动力学,半衰期分别为0.30、0.01、0.06和3.44小时。肝切片孵育中DPH和DPD的降解速率比DDAVP快得多,因此在培养基中观察到再生DDAVP的积累。相比之下,DPP的代谢比DDAVP慢得多,因此未检测到再生DDAVP的显著积累。
DDAVP与脂肪酸缀合增加了这种肽类药物的亲脂性和抗利尿活性。脂质化DDAVP的抗利尿活性取决于脂肪酸的链长以及缀合物中连接子的结构。缀合物体内抗利尿活性的保留和增强最可能是由于药代动力学行为的改善以及组织中活性DDAVP的同时再生。